Marksans Pharma Intrinsic Value
Marksans Pharma (MARKSANS) median intrinsic value is ₹405.86 from 9 valuation models (range ₹75–₹623), vs current price ₹249.27 — +62.8% upside (Trading Below Calculated Value), margin of safety 38.6%. For current market price and key ratios, visit Marksans Pharma stock price NSE.
MARKSANS Valuation Methods Summary — DCF, Graham Number & P/E
Marksans Pharma intrinsic value across 9 models vs current price ₹249.27 — upside/downside and value range per method. Also explore MARKSANS share price data to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹190.96 | ₹152.77 - ₹229.15 | -23.4% | EPS: ₹8.68, Sector P/E: 22x |
| Book Value Method | asset | ₹623.18 | ₹560.86 - ₹685.50 | +150.0% | Book Value/Share: ₹553.11, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹498.54 | ₹448.69 - ₹548.39 | +100.0% | Revenue/Share: ₹659.56, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹498.54 | ₹448.69 - ₹548.39 | +100.0% | EBITDA: ₹664.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹405.86 | ₹324.69 - ₹487.03 | +62.8% | CF Growth: 3.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹74.78 | ₹67.30 - ₹82.26 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹134.11 | ₹120.70 - ₹147.52 | -46.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹498.54 | ₹448.69 - ₹548.39 | +100.0% | ROE: 15.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹328.67 | ₹295.80 - ₹361.54 | +31.9% | EPS: ₹8.68, BVPS: ₹553.11 |
MARKSANS Intrinsic Value vs Market Price — All Valuation Models
Marksans Pharma fair value range ₹75–₹623 vs current market price ₹249.27 across 9 valuation models. Browse MARKSANS income statement for revenue, profit, balance sheet and cash flow data.
MARKSANS Intrinsic Value Analysis — Undervalued or Overvalued?
Marksans Pharma median intrinsic value ₹405.86, current price ₹249.27 — Trading Below Calculated Value by 62.8%, margin of safety 38.6%.
What is the intrinsic value of MARKSANS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Marksans Pharma (MARKSANS) is ₹405.86 (median value). With the current market price of ₹249.27, this represents a +62.8% variance from our estimated fair value.
The valuation range spans from ₹74.78 to ₹623.18, indicating ₹74.78 - ₹623.18.
Is MARKSANS undervalued or overvalued?
Based on our multi-method analysis, Marksans Pharma (MARKSANS) appears to be trading below calculated value by approximately 62.8%.
MARKSANS Financial Health — Key Ratios vs Industry Benchmarks
Marksans Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.07 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MARKSANS Cash Flow Quality — Operating & Free Cash Flow
Marksans Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹207 Cr | ₹183 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹230 Cr | ₹160 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹237 Cr | ₹108 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹99 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹179 Cr | ₹157 Cr | Positive Free Cash Flow | 8/10 |